On Monday, Lexaria Bioscience Corp (NASDAQ: LEXX) was -4.42% drop from the session before, before settling in for the closing price of $0.88. A 52-week range for LEXX has been $0.77 – $3.38.
Annual sales at Healthcare sector company grew by 21.61% over the past five years. When this article was written, the company’s average yearly earnings per share was at -44.68%. With a float of $20.41 million, this company’s outstanding shares have now reached $22.23 million.
Lexaria Bioscience Corp (LEXX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexaria Bioscience Corp stocks. The insider ownership of Lexaria Bioscience Corp is 8.19%, while institutional ownership is 10.34%. The most recent insider transaction that took place on Jul 29 ’25, was worth 14,375. In this transaction Director of this company bought 15,600 shares at a rate of $0.92, taking the stock ownership to the 270,012 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 11,900 for $0.91, making the entire transaction worth $10,866. This insider now owns 281,912 shares in total.
Lexaria Bioscience Corp (LEXX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 8/31/2024, it has been observed that the corporation posted -0.15 earnings per share (EPS) during the time that was less than consensus figure (set at -0.11) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -44.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.12% during the next five years compared to 21.61% growth over the previous five years of trading.
Lexaria Bioscience Corp (NASDAQ: LEXX) Trading Performance Indicators
You can see what Lexaria Bioscience Corp (LEXX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Lexaria Bioscience Corp (LEXX)
Lexaria Bioscience Corp (NASDAQ: LEXX) saw its 5-day average volume 0.65 million, a positive change from its year-to-date volume of 0.27 million. As of the previous 9 days, the stock’s Stochastic %D was 3.14%.
During the past 100 days, Lexaria Bioscience Corp’s (LEXX) raw stochastic average was set at 8.40%, which indicates a significant increase from 2.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1414 in the past 14 days, which was higher than the 0.0799 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9842, while its 200-day Moving Average is $1.3025. Nevertheless, the first resistance level for the watch stands at $0.8800 in the near term. At $0.9200, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9500. If the price goes on to break the first support level at $0.8100, it is likely to go to the next support level at $0.7800. The third support level lies at $0.7400 if the price breaches the second support level.
Lexaria Bioscience Corp (NASDAQ: LEXX) Key Stats
There are 19,559K outstanding shares of the company, which has a market capitalization of 18.67 million. As of now, sales total 460 K while income totals -5,800 K. Its latest quarter income was 170 K while its last quarter net income were -3,790 K.
